专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011011688A3 DENDRITIC CELL VACCINES FOR ASPARAGINYL- ß - HYDROXYLASE EXPRESSING TUMORS 审中-公开
标题翻译： ASPARAGINYL-ß-羟化酶表达肿瘤的树突状细胞疫苗
公开(公告)号：WO2011011688A3
公开(公告)日：2011-03-17
申请号：PCT/US2010043056
申请日：2010-07-23
申请人： RHODE ISLAND HOSPITAL , SHIMODA MASAFUMI , WANDS JACK R
发明人： SHIMODA MASAFUMI , WANDS JACK R
IPC分类号： A61K39/00 , C07K14/705
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/545 , C12N5/0639 , C12N9/0071 , C12N2500/90 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/52
摘要： A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH- expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines such as GM-CSF and IFN-?
摘要翻译：含有AAH成熟树突细胞的疫苗用于治疗哺乳动物受试者中表达AAH的肿瘤。通过使分离的树突细胞与抗原如AAH接触来进行产生引发的树突细胞的方法。在抗原接触步骤之后，使树突细胞与细胞因子如GM-CSF和IFN-γ的组合接触。

2. 发明申请

WO2009120891A3 DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS TO HEMATOPOIETIC LINEAGE CELLS 审中-公开
标题翻译：将原始细胞干细胞分化为HEMATOPOIETIC线细胞
公开(公告)号：WO2009120891A3
公开(公告)日：2010-01-07
申请号：PCT/US2009038442
申请日：2009-03-26
申请人： GERON CORP , TSENG SUYI , MAJUMDAR ANISH SEN , NISHIMOTO KEVIN , REDDY ANITA , LEBKOWSKI JANE
发明人： TSENG SUYI , MAJUMDAR ANISH SEN , NISHIMOTO KEVIN , REDDY ANITA , LEBKOWSKI JANE
IPC分类号： C12N5/00 , C12N5/0784
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N2501/02 , C12N2501/125 , C12N2501/155 , C12N2501/165 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/52 , C12N2506/02
摘要： Methods for differentiation of primate pluripotent stem cells into cells of hematopoietic lineage with a plurality of exogenous cytokines comprising granulocyte-macrophage colony stimulating factor (GMCSF) and bone morphogenic protein 4 (BMP-4) are disclosed.
摘要翻译：公开了将多种包含粒细胞 - 巨噬细胞集落刺激因子（GMCSF）和骨形态发生蛋白4（BMP-4）的外源性细胞因子分化为造血谱系细胞的灵长类多能干细胞的方法。

3. 发明申请

WO2009131712A2 REGULATORY B CELLS AND THEIR USES 审中-公开
标题翻译：调节B细胞及其用途
公开(公告)号：WO2009131712A2
公开(公告)日：2009-10-29
申请号：PCT/US2009/002560
申请日：2009-04-27
申请人： DUKE UNIVERSITY MEDICAL CENTER , TEDDER, Thomas, F. , YANABA, Koichi , BOUAZIZ, Jean-David
发明人： TEDDER, Thomas, F. , YANABA, Koichi , BOUAZIZ, Jean-David
IPC分类号： A61K35/14 , A61K39/395
CPC分类号： A61K35/17 , A61K2035/122 , A61K2035/124 , A61K2039/505 , C07K16/2887 , C07K2317/732 , C07K2317/734 , C12N5/0087 , C12N5/0635 , C12N2501/52
摘要： The present invention relates to a phenotypically distinct CD1d high CD5 + B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.
摘要翻译：本发明涉及通过分泌白细胞介素-10（IL-10）调节T细胞介导的炎性反应的表型不同的CD1dhighCD5 + B细胞亚群。本发明还涉及这些产生IL-10的调节性B细胞在免疫和炎症应答的操作以及疾病的治疗中的用途。描述了涉及过去转移这些调节性B细胞的治疗方法，或其控制自身免疫性或炎性疾病和病症的内源性水平的扩大。调节性B细胞亚群的消融或其IL-10产生的抑制可用于上调免疫缺陷状况和/或治疗肿瘤/癌症。还包括诊断应用程序。

4. 发明申请

WO2009054556A1 METHOD FOR PREPARATION OF THERAPEUTIC B CELLS AGAINST AUTOIMMUNE DISEASES WHICH ARE INDUCED BY AUTOIMMUNE CYTOTOXICITY 审中-公开
标题翻译：用于制备治疗性B细胞的方法，其抗自发免疫细胞毒性引起的自身免疫性疾病
公开(公告)号：WO2009054556A1
公开(公告)日：2009-04-30
申请号：PCT/KR2007/005245
申请日：2007-10-24
申请人： NAM, Sang Yun , LEE, Sang Mok , HA, Jong Cheon
发明人： NAM, Sang Yun , LEE, Sang Mok , HA, Jong Cheon
IPC分类号： A61K39/395 , A61K35/16 , A61P37/00
CPC分类号： C12N5/0635 , A61K39/0008 , A61K2035/124 , C12N2501/052 , C12N2501/23 , C12N2501/52
摘要： Disclosed is a method for the preparation of a cell therapeutic agent for autoimmune immune diseases based on the ability of B cells to control the differentiation of T cells, which are responsible for self tissue destruction. The method comprises (A) separating B cells from blood or bone marrow of an individual suffering from an autoimmune disease selected from among multiple sclerosis, type 1 diabetes mellitus, rheumatoid arthritis, and Hashimoto's thyroiditis; (B) primarily culturing the B cells in a culture medium supplemented with a B cell proliferation-inducing factor in the presence of an antigen causing the autoimmune disease! and (C) secondarily culturing the B cells in a fresh culture medium supplemented with a B cell proliferation-inducing factor in the presence of an antigen causing the autoimmune disease. A cell therapeutic agent therefor can be prepared. The cell therapeutic agent shows highly persistent therapeutic efficacy against autoimmune diseases, such as multiple sclerosis, type 1 diabetes mellitus, rheumatoid arthritis, and Hashimoto' s thyroiditis without side effects.
摘要翻译：公开了一种基于B细胞控制导致自身组织破坏的T细胞分化的能力来制备用于自身免疫性疾病的细胞治疗剂的方法。该方法包括（A）从患有多发性硬化，1型糖尿病，类风湿性关节炎和桥本氏甲状腺炎的自身免疫性疾病的个体的血液或骨髓中分离B细胞; （B）在引起自身免疫疾病的抗原存在下，在补充有B细胞增殖诱导因子的培养基中主要培养B细胞！和（C）在导致自身免疫性疾病的抗原存在下，在补充有B细胞增殖诱导因子的新鲜培养基中二次培养B细胞。可以制备其细胞治疗剂。细胞治疗剂对多发性硬化，1型糖尿病，类风湿性关节炎和桥本甲状腺炎等免疫性疾病具有高度持久的治疗效果，无副作用。

5. 发明申请

WO2003052083A2 MATERIALS AND METHODS RELATING TO THE PRODUCTION AND MAINTENANCE OF CELL LINES 审中-公开
标题翻译：与细胞生产和维护相关的材料和方法
公开(公告)号：WO2003052083A2
公开(公告)日：2003-06-26
申请号：PCT/GB2002/005753
申请日：2002-12-18
申请人： CANCER RESEARCH TECHNOLOGY LIMITED , SPITS, Hergen , NASPETTI, Marianne , SCHEEREN, Ferenc , BLOM, Bianca
发明人： SPITS, Hergen , NASPETTI, Marianne , SCHEEREN, Ferenc , BLOM, Bianca
IPC分类号： C12N5/00
CPC分类号： C07K14/4705 , C07K14/70567 , C07K2319/00 , C12N5/0635 , C12N2501/23 , C12N2501/392 , C12N2501/48 , C12N2501/52 , C12N2501/60 , C12N2510/02 , C12N2799/027
摘要： The invention provides methods for maintaining cell lines from primary cells, i.e. non-transformed cells, using expression of the signal transducer of activation and transcription (STAT). The methods are particularly suitable for the maintenance of B-cells.
摘要翻译：本发明提供了使用激活和转录（STAT）信号转导子的表达来维持来自原代细胞，即非转化细胞的细胞系的方法。该方法特别适用于维持B细胞。

6. 发明申请

WO02046376A1 DEHYDRATED ANTIGEN PRESENTING CELLS USABLE FOR VACCINATION 审中-公开
标题翻译：脱水抗原提供可用于疫苗接种的细胞
公开(公告)号：WO02046376A1
公开(公告)日：2002-06-13
申请号：PCT/EP2001/013354
申请日：2001-11-19
IPC分类号： A01N1/02 , A61K35/14 , A61K39/00 , C12N5/0784 , C12N5/0786 , C12N5/08 , C12N5/06
CPC分类号： C12N5/0645 , A01N1/02 , A01N1/0278 , A61K39/0011 , A61K2039/5154 , A61K2039/55561 , A61K2039/55594 , C12N5/0639 , C12N2500/72 , C12N2501/056 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/52
摘要： The invention relates to a dehydrated antigen presenting cells obtained from initial fresh antigen presenting cells and being liable to generate an immune response against the same antigen(s) as the one(s) against which the initial antigen presenting cells are directed.
摘要翻译：本发明涉及从初始新鲜抗原呈递细胞获得的脱水抗原呈递细胞，并且易于产生针对与初始抗原呈递细胞相对应的相同抗原的免疫应答。

7. 发明申请

WO02022648A2 COMPOSITIONS AND METHODS FOR INDUCING SPECIFIC CYTOLYTIC T CELL RESPONSES 审中-公开
标题翻译：用于诱导特异性CYPOLYTIC T细胞应答的组合物和方法
公开(公告)号：WO02022648A2
公开(公告)日：2002-03-21
申请号：PCT/US2001/028016
申请日：2001-09-06
IPC分类号： G01N33/53 , A61K35/14 , A61K39/00 , A61P31/00 , A61P35/00 , A61P37/02 , A61P37/08 , C07K14/725 , C12N5/0783 , C12N5/10 , C12N15/09 , C12Q1/02 , G01N33/50 , C07K
CPC分类号： C12N5/0636 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/57 , C12N2501/23 , C12N2501/52 , C12N2502/11 , G01N33/505
摘要： The invention provides a method of inducing CD8 T lymphocytes selective for a pathologically aberrant cell ex vivo. The method consists of contacting an apoptotic pathologically aberrant cell with a mixture having at least dendritic cells (DC), CD4 T cells and CD8 T lymphocytes, and culturing an apoptotic pathologically aberrant cell with the mixture for sufficient time to generate CD8 T lymphocytes (TL) having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell. The invention further provides a method of inducing CD8 TL selective for one or more target antigens ex vivo. The method consists of contacting one or more target antigens with a mixture having at least dendritic cells (DC), CD4 T cells, CD8 TL and IL-7, and culturing said one or more target antigens with the mixture for sufficient time to generate CD8 TL having selective immune reactivity toward one or more target antigens. The invention further provides a method of treating a patient having a disease mediated by a pathologically aberrant cell. The method consists of administering an effective amount of a CD8 TL produced by the methods of the invention having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell.
摘要翻译：本发明提供了诱导对体外病理异常细胞选择性的CD8 + T淋巴细胞的方法。该方法包括使凋亡病理学异常细胞与至少具有树突状细胞（DC），CD4 + T细胞和CD8 + T淋巴细胞的混合物接触，并用混合物培养凋亡性病理学异常细胞足够的时间产生具有针对病理学异常细胞的抗原特异性和/或选择性细胞溶解活性的CD8 + T淋巴细胞（TL）。本发明进一步提供一种对体外一种或多种靶抗原选择性地诱导CD8 + TL的方法。该方法包括使一种或多种靶抗原与至少具有树突状细胞（DC），CD4 + T细胞，CD8 + TL和IL-7的混合物接触，并用混合物培养所述一种或多种靶抗原足够的时间产生具有针对一种或多种靶抗原的选择性免疫反应性的CD8 + TL。本发明还提供了治疗由病理学异常细胞介导的疾病的患者的方法。该方法包括向病理异常细胞施用有效量的本发明方法产生的CD8 + TL具有抗原特异性和/或选择性细胞溶解活性。

8. 发明申请

WO0185207A2 MODULATION OF ANTIGEN PROCESSING 审中-公开
标题翻译：抗原加工调制
公开(公告)号：WO0185207A2
公开(公告)日：2001-11-15
申请号：PCT/US0114796
申请日：2001-05-07
申请人： UNIV ROCKEFELLER , ALBERT MATTHEW , BIRGE RAYMOND , JESATHESAN MITHILA , DARNELL JAMES E
发明人： ALBERT MATTHEW , BIRGE RAYMOND , JESATHESAN MITHILA , DARNELL JAMES E
IPC分类号： A61K39/00 , A61K48/00 , A61P37/06 , C12N5/0784
CPC分类号： A61K39/001 , A61K39/0008 , A61K48/00 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55511 , A61K2039/57 , C12N5/064 , C12N2501/04 , C12N2501/52 , C12N2501/58
摘要： The present invention is directed to methods for enhancing the ability of the immune system to either increase or decrease a cellular immune response to an antigen, for the purpose of either enhancing effectiveness of, for example, anti-viral and anti-tumor responses or decreasing immunological reactions in, for example, autoimmune disease or organ rejection, respectiely; or clearing certain antigens responsible for disease in order to prevent an immune response. Methods are also provided for preventing a cellular immune response to a pre-selected antigen by ex vivo of in vivo methods whereby dendritic cell maturation is permitted to occur in the absence of effective CD4+ T cell help. Under these conditions, elimination of cytotoxic T cells is achieved. The methods may be used for the prophylaxis of an undesired immune response to an autoimmune disease antigen, a transplant antigen, or reducing an exaggerated immune response to an antigen.
摘要翻译：本发明涉及用于增强免疫系统增加或减少对抗原的细胞免疫应答的能力的方法，以提高例如抗病毒和抗肿瘤反应的有效性或降低免疫反应，例如自身免疫性疾病或器官排斥反应; 或清除负责疾病的某些抗原，以防止免疫应答。还提供了用于通过离体体内方法来预防对预先选择的抗原的细胞免疫应答的方法，由此在没有有效的CD4 + T细胞帮助的情况下允许发生树突状细胞成熟。在这些条件下，实现细胞毒性T细胞的消除。该方法可用于预防对自身免疫性疾病抗原，移植抗原的不期望的免疫应答，或减少对抗原的夸大的免疫应答。

9. 发明申请

WO01051617A1 MONOCYTE-DERIVED DENDRITIC CELL SUBSETS 审中-公开
标题翻译：单克隆衍生的细胞宿主
公开(公告)号：WO01051617A1
公开(公告)日：2001-07-19
申请号：PCT/US2001/001162
申请日：2001-01-10
IPC分类号： A61K9/00 , A61K35/12 , A61K39/00 , C12N5/0784 , C12N5/06 , A61K39/385 , A61K48/00
CPC分类号： C12N5/0639 , A61K39/00 , A61K2035/122 , A61K2039/5154 , A61K2039/5158 , C12N5/064 , C12N2500/25 , C12N2500/36 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/52 , C12N2501/999
摘要： A novel subset of monocyte-derived dendritic cells are provided. Methods for producing these monocyte-derived dendritic cells and compositions comprising the dendritic cells of the invention are also provided. Methods for inducing an immune response to an antigen of interest using the dendritic cells of the invention are provided. Also provided are methods for therapeutically or prophylactically treating a disease in a subject suffering from the disease using the dendritic cells.
摘要翻译：提供了单核细胞衍生的树突状细胞的新亚型。还提供了用于制备这些单核细胞衍生的树突状细胞的方法和包含本发明的树突状细胞的组合物。提供了使用本发明的树突状细胞诱导感兴趣的抗原的免疫应答的方法。还提供了使用树突状细胞治疗或预防性治疗患有该疾病的受试者的疾病的方法。

10. 发明申请

WO1998021314A2 METHOD OF PROMOTING B-CELL PROLIFERATION AND ACTIVATION AND OF MODULATING THE IMMUNE SYSTEM 审中-公开
标题翻译：促进B细胞增殖和激活和调节免疫系统的方法
公开(公告)号：WO1998021314A2
公开(公告)日：1998-05-22
申请号：PCT/US1997021858
申请日：1997-11-12
申请人： DANA-FARBER CANCER INSTITUTE , SCHULTZE, Joachim, L. , FREEMAN, Gordon, J. , GRIBBEN, John, G. , NADLER, Lee, M.
发明人： DANA-FARBER CANCER INSTITUTE
IPC分类号： C12N05/08
CPC分类号： C12N5/0635 , A61K38/00 , C12N2501/04 , C12N2501/23 , C12N2501/52
摘要： We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large numbers. These cells can be activated in vitro by coculture with CD40L (CD40-B cells) and an immunosuppressive agent such as cyclosporin A. They can be expanded up to 1 x 10 to 1 x 10 fold in 2 weeks or 1 x 10 to 1 x 10 fold in 2 months. We demonstrate these cells are most efficient APCs comparable to DCs in stimulating allogeneic CD4 CD45RA , CD4 , CD45RO , and CD8 T cells. In contrast to DCs, CD40-B cells are fully functional even in the presence of immunosuppressive cytokines such as IL-1O and TGF beta .
摘要翻译：我们教授一种策略，以获得大量所需的APC，活化的B细胞，其在多重给药方案中具有优于其呈递肿瘤蛋白抗原的能力。人B细胞可以从外周血大量获得。这些细胞可以通过与CD40L（CD40-B细胞）和免疫抑制剂如环孢菌素A的共培养在体外进行活化。它们可以在2周内扩增至1×10 3至1×10 4倍，或 2个月内1×10 5至1×10 6。我们证明这些细胞是最有效的APC，与刺激同种异体CD4 + CD45RA +，CD4 +，CD45RO +和CD8 + T细胞的DC相当。与DC相反，即使在存在免疫抑制性细胞因子如IL-10和TGFβ的情况下，CD40-B细胞也是完全功能的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式